Thrombosis
From the Journals
AVERT: Apixaban reduced thromboembolism risk in cancer patients
Cancer patients treated with apixaban had a significantly lower rate of venous thromboembolism but a higher risk of major bleeds than did those...
Conference Coverage
DOAC pause yields favorable outcomes for AF patients
SAN DIEGO – Results from the PAUSE study could set the standard for timing of perioperative DOAC interruption.
Video
ARISTOPHANES: Apixaban edges other DOACS for octogenarians
CHICAGO – Insurance claims data from more than 50,000 U.S. octogenarians on a DOAC showed apixaban worked best and caused the fewest major bleeds...
Guidelines
ASH releases new VTE guidelines
A panel of the American Society of Hematology released more than 150 recommendations for dealing with venous thromboembolism.
Conference Coverage
Tofacitinib and TNF inhibitors show similar VTE rates
A review of more than 50,000 U.S. rheumatoid arthritis patients shows similar venous thromboembolism rates with tofacitinib and TNF inhibition.
From the Journals
All patients with VTE have a high risk of recurrence
Researchers suggest rethinking categorization of patients with incident venous thromboembolism.
Conference Coverage
Prolonged DAPT doesn’t help left main CAD
SAN DIEGO – An analysis of the EXCEL trial shows no benefit in patients who took DAPT for 3 years, compared with those who stopped it sooner.
Feature
Apixaban is safest effective DOAC for stroke prevention in Afib, per AHRQ report
The agency found the lowest bleeding risk with apixaban, but cites lack of head-to-head trials as a limitation in evaluating DOACs.
Conference Coverage
CT opens extended window for stroke thrombolysis
MONTREAL – The new EXTEND findings “will have a major impact” on using an extended time window for thrombolysis in U.S. practice.
Conference Coverage
EHR-guided strategy reduces postop VTE events
BOSTON – Missed doses of enoxaparin correlate with increased incidence of deep vein thrombosis.
Conference Coverage
Stroke risk in elderly following AMI extends to 12 weeks
ATLANTA – The prolonged period of heightened risk was evident in patients with both STEMI and NSTEMI.